NICE has called on pharmaceutical companies to question the development costs of new medicines.In a letter to The Times (set out below), Sir Andrew Dillon, Chief Executive of NICE, acknowledged the expense of bringing new drugs to market but said that health services had to be confident that the extra benefits for patients justified the price.Sir Andrew was responding to commentary by the business editor at The Times, Ian King, who argued the NICE's decisions could influence the choice of drug companies to locate in the UK.  For more details, go to: http://www.nice.org.uk/newsroom/news/NICERespondsToArticleInTheTimes.jsp